Loading...
01/11 03:11
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company reported strong financial performance with significant revenue growth and improved EBITDA. New product launches and successful adoption, especially in pain and appendage management, support positive sentiment. Despite challenges in the MIS segment, management's strategic approach and positive outlook on upcoming clinical trials and market differentiation are encouraging. The Q&A session reinforced optimism with positive analyst feedback on product adoption and strategic plans. Given the small-cap nature, a 2-8% positive stock price movement is expected over the next two weeks.
Total Revenue $124,000,000 (14% growth) year-over-year, driven by strong performance in pain management and appendage management franchises.
Adjusted EBITDA $9,000,000 (more than 200% increase) year-over-year, reflecting improved profitability.
U.S. Revenue $101,100,000 (12.1% increase) year-over-year, with strong demand for new products.
Open Ablation Product Sales $33,300,000 (13.7% increase) year-over-year, led by Encompass clamps.
U.S. Sales of Appendage Management Products $42,100,000 (17.3% increase) year-over-year, driven by demand for AtriClip Flex Mini.
Minimally Invasive Ablation Sales $8,500,000 (approximately 31% decline) year-over-year, due to pressure from PFA catheters.
U.S. Pain Management Sales $17,300,000 (35.6% increase) year-over-year, propelled by Cryosphere MAX probe.
International Revenue $22,500,000 (20.8% increase) year-over-year, with European sales up 25.1%.
Gross Margin 74.9% (up 27 basis points) year-over-year, driven by product mix and operational efficiencies.
Operating Expenses $98,600,000 (6.9% increase) year-over-year, due to increased R&D and modest SG&A growth.
Loss Per Share $0.14 (improved from $0.28) year-over-year.
Adjusted Loss Per Share $0.14 (compared to $0.25) year-over-year.
Cash and Investments Approximately $100,000,000 at the end of the quarter, with cash burn declining by $8,000,000 year-over-year.
AtriClip Flex Mini: The AtriClip Flex Mini device features the smallest profile of any open chest LAA closure device on the market today, with adoption doubling since launch.
AtriClip Pro Mini: Received 510 clearance for a minimally invasive AtriClip Pro Mini device, which is 60% smaller than the next lowest profile device, enhancing visualization and precise placement.
Cryo XT Probe: FDA clearance received for Cryo XT probe designed for extremity amputations, expected to launch later this year.
Worldwide Appendage Management Revenue: Grew 19%, driven by 23% growth in open AtriClip devices and 7% growth in MIS appendage management devices.
International Revenue: Totaled $22,500,000, up 20.8% on a reported basis, with European sales accounting for $14,200,000, up 25.1%.
Open Ablation Franchise Growth: Experienced 14% growth in the first quarter, including over 47% growth in sales of the Encompass clamp.
Adjusted EBITDA: Reported $9,000,000 for the first quarter, representing an improvement of over 200% from the first quarter of 2024.
Gross Margin: For the first quarter was 74.9%, up 27 basis points from the first quarter of 2024, driven by product mix and operational efficiencies.
Analyst and Investor Day: Outlined vision to remain a leader in multibillion dollar markets, focusing on product development, clinical research, and therapy development.
LEAPS Trial Enrollment: Reached total enrollment of 5,500 patients, aiming for 6,500 by the third quarter, to demonstrate the benefit of managing the appendage with an AtriClip device.
Regulatory Issues: The company faces risks related to regulatory approvals and clearances for its products, which could impact market opportunities and growth initiatives.
Competitive Pressures: AtriCure is experiencing competitive pressures in the market, particularly with the introduction of new products by competitors, which could affect market share and pricing.
Supply Chain Challenges: The company acknowledges potential modest impacts from tariffs and trade restrictions, although it is primarily insulated due to U.S. manufacturing and sourcing.
Economic Factors: Economic conditions and healthcare costs are factors that could influence patient treatment decisions and overall market demand for AtriCure's products.
Clinical Trial Outcomes: The success of ongoing clinical trials, such as the LEAPS trial, is critical; unfavorable outcomes could hinder product adoption and market growth.
Market Adoption: There is uncertainty regarding the adoption rates of new products, such as the AtriClip Flex Mini and Cryo XT, which could affect revenue projections.
Minimally Invasive Surgery (MIS) Pressure: The company is facing downward pressure in its MIS segment due to competition from PFA catheters, which may impact future sales.
Revenue Growth: AtriCure achieved total revenue of $124 million, reflecting a 14% growth, driven by strong performance in pain management and appendage management franchises.
Adjusted EBITDA: Reported adjusted EBITDA of $9 million for Q1, representing over 200% improvement from Q1 2024.
Product Development Investments: AtriCure is focused on investments in product development, clinical research, and therapy development to maintain leadership in multibillion dollar markets.
AtriClip Flex Mini Adoption: The AtriClip Flex Mini device has seen rapid adoption, contributing over 15% of U.S. open appendage management revenue.
LEAPS Trial Enrollment: Enrollment for the LEAPS trial reached 5,500 patients, with a target of 6,500 by Q3, aiming to demonstrate the benefits of appendage management.
Cryo XT Probe Launch: The Cryo XT probe, designed for extremity amputations, is expected to launch later this year, expanding the addressable market.
2025 Revenue Guidance: AtriCure expects full year revenue of $517 million to $527 million, reflecting 11% to 13% growth over 2024.
Adjusted EBITDA Guidance: Adjusted EBITDA is expected to be between $44 million to $46 million for 2025, translating to an adjusted loss per share of approximately $0.50 to $0.55.
Q2 Revenue Expectations: For Q2, AtriCure anticipates mid-single digit sequential growth, with minimal improvement in U.S. MIS ablation and appendage management revenue.
Gross Margin Outlook: Gross margin for 2025 is expected to be consistent with 2024, with potential impacts from cost-saving initiatives.
Adjusted EBITDA: $8,800,000 for Q1 2025, compared to $2,800,000 for Q1 2024, representing over 200% increase.
Cash and Investments: Approximately $100,000,000 at the end of Q1 2025.
Full Year Revenue Guidance: $517,000,000 to $527,000,000, reflecting growth of 11% to 13% over 2024.
Adjusted EBITDA Guidance: $44,000,000 to $46,000,000 for full year 2025.
Loss per Share Guidance: Approximately $0.50 to $0.55 for full year 2025.
Cash Burn: Declined by $8,000,000 from Q1 2024.
The earnings call reflects strong product development, market expansion, and optimistic guidance, with new launches and international growth. Adjusted EBITDA guidance was raised, indicating financial health. The Q&A highlighted sustained growth in key segments and strategic focus on underpenetrated markets. While some uncertainties remain, the overall sentiment is positive, with a market cap indicating potential for significant stock movement.
The earnings call showed a mix of positive and negative elements. Strong product development and market expansion are counterbalanced by guidance indicating slowed growth and flat EBITDA. The Q&A reveals cautious optimism but acknowledges competitive pressures and uncertainties, especially in the MIS business. The market cap indicates potential for moderate stock movement, resulting in a neutral sentiment.
The earnings call shows mixed signals: strong revenue growth and product launches are positive, but uncertainties in market adoption and a lack of shareholder return plans are concerning. The Q&A reveals optimism in product adoption and financial metrics but also highlights pressure in certain business areas. The reaffirmed guidance and improved EBITDA are positive, but the lack of a buyback or dividend plan and some management evasiveness temper enthusiasm. Given the company's small market cap, the stock price is likely to remain stable in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
